|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM186561768 |
| 003 |
DE-627 |
| 005 |
20250210051430.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.01.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0622.xml
|
| 035 |
|
|
|a (DE-627)NLM186561768
|
| 035 |
|
|
|a (NLM)19230777
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Loftus, B
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.05.2009
|
| 500 |
|
|
|a Date Revised 15.11.2012
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a An open-label dose escalation study of T-cell vaccination in multiple sclerosis patients was conducted using attenuated myelin reactive T-cells (MRTC) selected with six myelin peptides, two each from MBP, PLP and MOG. The dose range of subcutaneous injections given at weeks 0, 4, 12 and 20 was 6-9E6, 30-45E6 and 60-90E6 irradiated MRTC. Assessments were over 52 weeks for MRTC levels, EDSS, MSIS-29, brain MRI and relapses. The 30-45E6 dose was the most effective with reductions in MRTC ranging from 92.4% at week 5 to 64.8% at week 52. The reduction in relapses compared to baseline for the M-ITT and evaluable per-protocol analyses were 63.5%, and 85.0% at week 52. The MRI lesions were stable while there was an improvement trend in the EDSS and MSIS-29 physical subscore following the second injection. Adverse events were mild to moderate in intensity with mild injection site reactions occurring with increasing dosage. The mid-dose was selected for further clinical development studies because of the rapid depletion of peripheral blood MRTC and a trend for improvements in clinical outcomes following immunization
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Immunologic Factors
|2 NLM
|
| 650 |
|
7 |
|a Myelin Basic Protein
|2 NLM
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Vaccines, Attenuated
|2 NLM
|
| 650 |
|
7 |
|a Vaccines, Subunit
|2 NLM
|
| 650 |
|
7 |
|a tovaxin
|2 NLM
|
| 700 |
1 |
|
|a Newsom, B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montgomery, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Von Gynz-Rekowski, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Riser, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Inman, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Garces, P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rill, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Williams, J C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 131(2009), 2 vom: 15. Mai, Seite 202-15
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:131
|g year:2009
|g number:2
|g day:15
|g month:05
|g pages:202-15
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.01.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 131
|j 2009
|e 2
|b 15
|c 05
|h 202-15
|